Business Context and Reporting Period
Company: CRISPR Therapeutics AG
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2019
Event: Notification of a USPTO interference proceeding regarding CRISPR/Cas9 genome editing technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal event and does not contain financial statements.
Material Changes
Patent Interference Initiated: The USPTO Patent Trial and Appeal Board (PTAB) declared Patent Interference No. 106,115. This proceeding involves:
- CVC Group: University of California, University of Vienna, and Dr. Emmanuelle Charpentier (pending applications).
- Broad Institute: Broad Institute, Harvard University, and MIT (issued patents and pending applications).
Company Interest: CRISPR Therapeutics holds an exclusive worldwide license in human therapeutics to Dr. Charpentier's rights as a co-owner of the CVC portfolio.
Excluded Patents: Six new US patents issued to the CVC Group since June 2018 are not involved in this interference.
Guidance, Outlook, and Risks
Risks and Contingencies: The initiation of the interference proceeding represents a material legal contingency. The outcome could impact the validity or scope of the patents underlying the Company's exclusive license in human therapeutics.
Management Commentary: The filing provides factual notification of the event but does not include forward-looking guidance, financial outlook, or specific management commentary on the expected duration or outcome of the proceeding.
Investor Verification Checklist
- Verify the specific claims within the CVC Group's pending applications and Broad's issued patents involved in Interference No. 106,115.
- Assess the potential impact of the interference outcome on the Company's exclusive license rights in human therapeutics.
- Monitor future filings for updates on the PTAB proceedings and any related litigation.
- Confirm that the six CVC patents issued since June 2018 remain unaffected by this specific interference.